A5079051965- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Vasculitis and related conditions
- Immunodeficiency and Autoimmune Disorders
- Spondyloarthritis Studies and Treatments
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Biosimilars and Bioanalytical Methods
- COVID-19 Clinical Research Studies
- Cytokine Signaling Pathways and Interactions
- Psoriasis: Treatment and Pathogenesis
- Inflammasome and immune disorders
- Long-Term Effects of COVID-19
- Urticaria and Related Conditions
- Musculoskeletal Disorders and Rehabilitation
- Cancer Immunotherapy and Biomarkers
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- SARS-CoV-2 and COVID-19 Research
- Systemic Sclerosis and Related Diseases
- CAR-T cell therapy research
LMU Klinikum
2016-2025
Ludwig-Maximilians-Universität München
2016-2025
University College London
2023
Rigshospitalet
2023
Deutsche Gesellschaft für Urologie
2020-2023
Center for Rheumatology
2012-2022
Institut für Urheber- und Medienrecht
2013-2022
Asklepios Klinik Altona
2022
Heidelberg University
2021
University Hospital Heidelberg
2021
Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of is associated with side effects. The effect interleukin-6 receptor alpha inhibitor tocilizumab on rates relapse during glucocorticoid tapering was studied in patients giant-cell arteritis.In this 1-year trial, we randomly assigned 251 patients, a 2:1:1:1 ratio, to receive subcutaneous (at dose 162 mg) weekly or every other week, combined 26-week prednisone taper, placebo taper over period either...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that being investigated as targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis.In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were randomly assigned, in 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 placebo 3 months followed by or daily. The primary end points, assessed at month the percentage with least 20% improvement American College...
Abstract Objective To delineate the role of Th17 cells in pathogenesis autoimmune arthritides. Methods were analyzed well‐defined homogeneous cohorts patients with prototypical arthritides rheumatoid arthritis (RA) and psoriatic (PsA), grouped according to who had very early active RA (n = 36; mean disease duration 2.8 months, Disease Activity Score 28 joints 5.0) those PsA 20; 2.3 months), none whom received treatment glucocorticoids or disease‐modifying antirheumatic drugs, as well...
Abstract Objective To investigate whether Treg cells can suppress osteoclast differentiation, and to define a new potential link between the immune system skeleton. Methods Regulatory CD4+,CD25+,Foxp3+ T were isolated purified from spleen cocultured with CD11b+ precursor bone marrow. Osteoclastogenesis erosion assessed by tartrate‐resistant acid phosphatase staining pit resorption assay, respectively. In addition, Transwell experiments cytokine‐blocking performed mechanisms of interaction...
To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA).42 active PsA fulfilling ClASsification for Psoriatic ARthritis (CASPAR) criteria were randomly assigned (2:1) to receive two intravenous secukinumab doses (10 mg/kg; n=28) or placebo (n=14) 3 weeks apart. The primary endpoint was proportion American College Rheumatology (ACR) 20 responses at week 6 versus (one-sided p<0.1).Primary...
<h3>Objectives</h3> Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management largely empirical. This the first clinical study to determine if interleukin (IL)-18 inhibition, using recombinant human IL-18 binding protein, tadekinig alfa, therapeutic option in AOSD. <h3>Methods</h3> In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment prednisone and/or...
The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and disease caused by SARS-CoV-2, COVID-19 are meant for patients with rheumatic musculoskeletal diseases (RMD) their caregivers. A task force 20 members was convened that met times videoconferencing in April 2020. finally agreed on five overarching principles 13 covering four generic themes: (1) General measures prevention SARS-CoV-2 infection. (2)...
Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence these lack guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification management.First, group formulated research questions systematic literature review. Then, based on using consensus procedure, 4...
To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).We analysed the Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD for RA at clinical onset (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 (IL-6i) tumour necrosis factor (TNFi, reference group). The ordinal severity...
Introduction Whether patients with inflammatory rheumatic and musculoskeletal diseases (RMD) are at higher risk to develop severe courses of COVID-19 has not been fully elucidated. Aim this analysis was describe RMD according their severity identify factors for hospitalisation. Methods Patients PCR confirmed SARS-CoV-2 infection reported the German registry from 30 March 1 November 2020 were evaluated. Multivariable logistic regression used estimate ORs hospitalisation due COVID-19. Results...
Systemic sclerosis, a severe inflammatory autoimmune disease, shares common thread with cancer through the underlying mechanism of inflammation. This milieu not only drives immune dysregulation characteristic diseases but also plays pivotal role in pathogenesis cancer. Among cellular components involved, B cells have emerged as key players hematologic tumor and contributing to persistent tissue fibrosis systemic well progression evasion Consequently, novel therapeutic strategies targeting...
Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice patients inflammatory arthritis (IA) and history cancer. To perform systematic literature review to inform Task Force formulating EULAR points consider on the initiation targeted IA Specific research questions were defined within before exact queries librarian. We included studies reporting relative measure cancer initiating therapy or conventional synthetic...
Objective. Interleukin-10 (IL-10) has been shown to exert both antiinflammatory and immunostimulatory effects in vivo vitro. We therefore sought examine the role of this cytokine rheumatoid arthritis (RA) by assessing serum synovial fluid IL-10 levels. Methods. Serum samples were collected from patients with RA various inflammatory, infectious, noninflammatory arthritides (controls). was assayed using an IL-10-specific enzyme-linked immunosorbent assay, messenger RNA (mRNA) levels assessed...
Abstract Introduction Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective this study was evaluate the safety and clinical outcomes in several standard-of-care-refractory (within rheumatology, nephrology, dermatology neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma real-life setting. Methods Patients received having shown an inadequate...
Chaperonins have classically been thought of as intracellular molecules involved in the correct folding proteins.Their expression is upregulated during times stress such heat (hence their common nomenclature shock proteins [HSP]), anoxia, hypoglycaemia and reactive oxygen species [1].These are conditions found infected tissues or with chronic inflammation rheumatoid synovium.In location they protect cell from apoptotic death due to stress.Increasingly chaperonins recognised subserve...
Objectives MicroRNAs (miRNAs) have been implicated in the pathogenesis of autoimmune diseases, not least for their critical role regulation regulatory T cell (Treg) function. Deregulated expression miR-146a and miR-155 has associated with rheumatoid arthritis (RA). We therefore investigated Tregs patients RA possible impact on Treg function disease activity. Methods Expression was assessed controls. MiRNA correlated activity target genes. Interference biological miRNAs evaluated functional...
Systemic lupus erythematosus (SLE) is a complex, multisystem autoimmune disorder, which often involves referral to multiple medical specialists. Lupus nephritis (LN) occurs in ~35% of adults with SLE and predicts poor survival. There currently no consensus on how manage patients or LN across specialties different European countries. The Nephritis Terminology Advisory Group was formed address this issue as it impacts upon treatment. It has developed statements based opinions from expert panel...